RX Biosyent Inc

BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that CEO Rene
Goehrum will be making a presentation at the 2014 Bloom Burton & Co. Healthcare
Investor Conference at 4:30pm (ET), June 18, 2014 at the Toronto Board of Trade.
Mr. Goehrum will provide an overview of the Company and its corporate
activities.


Mr. Goehrum will be available for 1:1 meetings on the day of his
presentation.These meetings can be arranged via the conference organizers
http://www.bloomburton.com/conference/.


BioSyent also announces the grant of 17,031 incentive stock options to certain
employees and officers of the Company. These incentive stock options are
exercisable at a price of $7.45 up to June 12, 2024.


For a direct market quote (15 minutes delay) for the TSX Venture Exchange and
other Company financial information please visit www.tmxmoney.com.


About BioSyent Inc.

Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent
is a profitable growth oriented specialty pharmaceutical company which searches
the globe to in-license or acquire innovative pharmaceutical products that have
been successfully developed, are safe and effective, and have a proven track
record of improving the lives of patients and supporting the healthcare
professionals that treat them.


Once a product of interest has been found, BioSyent then acquires the exclusive
rights to the product and manages it through the Canadian governmental
regulatory approval process. Once approved, BioSyent markets the product
throughout Canada. 


At the date of this press release the Company had 13,801,195 shares issued and
outstanding.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Mr. Rene C. Goehrum
President and CEO
BioSyent Inc.
Tel: (905) 206-0013
investors@biosyent.com
www.biosyent.com

Biosyent (TSXV:RX)
Historical Stock Chart
From Mar 2024 to Apr 2024

Biosyent (TSXV:RX)
Historical Stock Chart
From Apr 2023 to Apr 2024